TechandBio
3 months ago
https://fintel.io/i/van-herk-investments
% ?Ownership
File Date
Form
Security
Prev
Shares
Current
Shares
?Shares %
% Ownership
% ?Ownership
2025-02-14 13G/A PRQR / ProQR Therapeutics N.V. 8,170,254 11,461,995 40.29 10.90 7.92
2024-04-26 13G DMTKQ / DermTech, Inc. 1,628,057 1,778,057 9.21 5.10 6.25
DMTKQ is three cent stock Wowza
$PRQR
TechandBio
3 months ago
ProQR shares plummet as eye disease treatment flops ...
Fierce Biotech
https://www.fiercebiotech.com βΊ biotech βΊ proqr-treatm...
Feb 11, 2022 β ProQR's treatment for a congenital eye disease in children failed to improve vision and mobility, a tough pill to swallow that Wall Street ...
Missing: prqr ?| Show results with: prqr
ProQR to Cut 30% of Workforce, CSO Following ...
BioSpace
https://www.biospace.com βΊ News βΊ Drug Development
Apr 13, 2022 β In February, ProQR reported that Phase II/III clinical trials of sepofarsen failed to meet both primary and secondary endpoints. Sepofarsen is a ...
Missing: prqr ?| Show results with: prqr
ProQR eye drug comes up short in key study, surprising ...
BioPharma Dive
https://www.biopharmadive.com βΊ news βΊ proqr-lca-ey...
Feb 11, 2022 β The biotech's treatment did not improve vision in the Phase 2/3 trial, a significant setback that sent shares down by 75%.
$PRQR
TechandBio
3 months ago
PRQR is an Eli Lilly oligonucleotide RNA Editing Platform 17.1% ownership New Next generation Platform with huge indications like obesity and cardiovascular diseases Lily will be able to manufacture these drugs for them. Never Seen Lily own so much of a small cap company and make milestone payments on them so soon. These Milestones so far will reach close to 4 Billion dollars and payments have commenced.
Eli Lilly made a 25M Royalty payment in 2024 vs. $3.9B in potential milestone payments so far 5 more indications lily totaling 15 indications and cash runway for over the next 2.5 years. βLillyβ has 95 appearances in their annual report.
PRQR has 2 founders plus chief CMO from Analyam the leader in RNAI 31 Billion company
1. Martin Maier, PhD
Martin Maier, PhD, joined our board in 2024. Dr. Maier currently serves as Senior Vice President, Oncology at Alnylam Pharmaceuticals. Dr. Maier joined Alnylam in 2006 and has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, and the advancement of multiple therapeutic programs to development, which has resulted in the approval of five RNAi therapeutic to date.
2.Phillip D. Zamore, PhD
Phillip is a Howard Hughes Medical Institute Investigator, Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute at the University of Massachusetts Medical School. He is also a co-founder of Alnylam Pharmaceuticals
3.John Maraganore, PhD, joined as a strategic advisor to our Board in March 2022. He served as the founding Chief Executive Officer and a Director of Alnylam from 2002 to 2021, where he built the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®. At Alnylam, he also led the companyβs value creation strategy, building $ 25.0 billion in market capitalization
No other company has all key executives of Alnylam connected to any team in Biotech.
lastly
A. Peter Beal, PhD
Peter was appointed as ProQR's Chief ADAR Scientist in December 2024. Peter is a Professor in the Department of Chemistry at the University of California at Davis and Director of the NIH-funded UC Davis Chemical Biology Graduate Program. For over 25 years, work in the Beal laboratory has advanced understanding of the structures and mechanism of action for the ADAR enzymes responsible for adenosine to inosine RNA editing in humans. In addition, his group has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for recruitment of RNA-binding proteins including ADARs. Beal teaches organic chemistry at the undergraduate level and several classes in nucleic acids chemistry and chemical biology at the graduate level. He has authored over 100 peer-reviewed publications in the field of RNA chemical biology and mentored over 50 Ph.D. and M.S. degree students.
I will be buying up shares up to $2.00 today.
My thoughts are hold for 2 years you have a high probability of success maximizing profits and a buyout from LILY or Alnylam Pharmaceuticals. for 1.5-2 Billion similar to Roche buying Poseida for a total of 1.5 Billion last year early stage gene editing company.
PRQR has close to 30 Indications in their pipeline 15 of them with ELI Lilly
$PRQR
TechandBio
3 months ago
54.36% owned by Institutions[ thats not including Eli Lilly & Van Herk thats another 27.2% =81.5%+ Insiders 14.5% 95% dirk haussecker north 2% M28 Capital 1%
98% of PRQR shares are accounted for
Adage Capital Partners GP L.L.C. 9.6M Dec 31, 2024 11.76% 16,707,967
Privium Fund Management B.V. 4.99M Dec 31, 2024 6.10% 8,675,001
Woodline Partners LP 3.56M Dec 31, 2024 4.35% 6,189,181
Affinity Asset Advisors, Llc 2.83M Dec 31, 2024 3.46% 4,915,500
Millennium Management Llc 2.83M Dec 31, 2024 3.46% 4,919,467
UBS Group AG 2.31M Dec 31, 2024 2.83% 4,019,487
Sio Capital Management, LLC 2.05M Dec 31, 2024 2.52% 3,574,991
Kynam Capital Management, LP 1.75M Dec 31, 2024 2.14% 3,045,000
Siren, L.L.C. 1.57M Dec 31, 2024 1.93% 2,740,500
DAFNA Capital Management, LLC 1.57M Dec 31, 2024 1.92% 2,727,556
Eli Lilly owns 16.1% check the filings if you don't believe me not included in institutional ownership Largest Pharma company in the world
Van Herk Investments B.V.owns 11.1% not included in institutional ownership (one of the largest real estate holders in Europe)
=81.6% roughly including Lilly & Van Herk
Insiders own 14.5%
96% of the shares are spoken for remember dirk haussecker owns 2% and M28 Capital owns over a million shares and Keeps adding shares.
There are no shares Floating around. If you can see the asymmetric upside here place your bets. I bought a chunk of the shares today and need another 863k shares.
WVE 1.6 Billion
PRQR 184 Million superior technology Patent protection Partnerships and Team
$PRQR